ArticleScientific reports2025
Dual therapeutic potential of Scoparia dulcis in combating hyperglycemia and inflammation in diabetes through network pharmacology and in silico analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic low-grade inflammation is a key contributor to the pathogenesis and complications of diabetes, leading to issues such as joint pain, skin disorders, periodontal disease, and neuropathy. Therefore, targeting inflammatory pathways has emerged as a promising therapeutic strategy for both the prevention and management of diabetes and its associated comorbidities. Natural products with dual anti-inflammatory and antidiabetic properties have gained significant interest, with Scoparia dulcis showing notable therapeutic potential. This study aimed to evaluate the efficacy of this herbal medicine in alleviating inflammation in diabetic patients using an integrative in silico approach, incorporating network pharmacology, molecular docking, and molecular dynamics simulations. Initial screening of compounds focused on their ability to inhibit key pathological targets implicated in diabetes-related inflammation. Pathway enrichment analysis revealed significant involvement in the AGE-RAGE signaling pathway, lipid metabolism, atherosclerosis pathways, and the hypoxia-inducible factor 1 (HIF-1) pathway. Ten critical molecular targets were identified, with TNF-α being the most prominent. Molecular docking followed by 200 ns molecular dynamics simulations assessed the binding affinity of TNF-α with the top ten selected compounds, revealing strong and stable interactions with essential active site residues. Furthermore, ADMET analysis and density functional theory (DFT) evaluations highlighted the therapeutic potential of these compounds as promising lead candidates for drug development. Existing literature supports the antidiabetic effects of these bioactive compounds, reinforcing the in silico findings. Thus, Scoparia dulcis represents a potential adjunct or alternative therapy for diabetic patients with chronic inflammation, offering a multifaceted approach to disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.